Novo Holdings invests in macrocycle startup Orbis as once-overlooked molecules get new interest
2024-02-29
At long last, macrocycles are spinning into the spotlight.
On Thursday, Orbis Medicines launched with €26 million in seed funding from European VC fund Forbion and Novo Holdings, the investment arm of Novo Nordisk’s parent foundation. The startup is focused on developing peptide drugs based on macrocycles, which are small chemical rings.
Most macrocycle drugs, such as cyclosporine or a component of Neosporin, have been discovered in nature, but the molecules were for a long time left on the sidelines by drug developers because they had difficulty passing through membranes, an important quality for many pill-based medicines. However, recent advances in designing peptides have shown it’s possible to overcome that obstacle and have rekindled interest in the potential for macrocyclic medicines.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。